HC Wainwright Reaffirms “Buy” Rating for Alumis (NASDAQ:ALMS)

Alumis (NASDAQ:ALMS)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $15.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 219.15% from the company’s previous close. HC Wainwright also issued estimates for Alumis’ Q1 2025 earnings at ($1.29) EPS, Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.01) EPS, Q4 2025 earnings at ($1.01) EPS and FY2025 earnings at ($4.26) EPS.

ALMS has been the topic of a number of other reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a research report on Thursday, March 20th. Oppenheimer initiated coverage on shares of Alumis in a research report on Thursday, January 30th. They set an “outperform” rating and a $32.00 price target on the stock. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $26.00.

Alumis Trading Down 4.5 %

Shares of ALMS stock opened at $4.70 on Wednesday. Alumis has a fifty-two week low of $3.18 and a fifty-two week high of $13.53. The business’s 50 day moving average price is $5.43 and its 200-day moving average price is $8.38.

Institutional Investors Weigh In On Alumis

Several large investors have recently bought and sold shares of ALMS. Charles Schwab Investment Management Inc. bought a new stake in Alumis in the 3rd quarter worth approximately $1,160,000. BNP Paribas Financial Markets bought a new stake in shares of Alumis in the third quarter worth $27,000. MetLife Investment Management LLC purchased a new stake in Alumis during the third quarter valued at $89,000. Maven Securities LTD lifted its holdings in Alumis by 100.0% in the third quarter. Maven Securities LTD now owns 50,000 shares of the company’s stock valued at $534,000 after acquiring an additional 25,000 shares during the period. Finally, Samsara BioCapital LLC purchased a new position in Alumis in the third quarter worth about $34,886,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.